Trinity Biotech has completed the acquisition of the specialty clinical chemistry product line from Sigma Diagnostics, a division of the Sigma Aldrich.
Trinity Biotech said the clinical chemistry business consists of the specialty products ACE, Bile Acids, Lactate, Oxalate, and G6PDH.
Trinity Biotech said it also gained the rights to an HbA1c product that is FDA cleared but not currently on the market.
The expected impact of the acquisition on earnings will be neutral in 2002 and earnings will be enhanced in 2003, it said.
"This acquisition gives Trinity Biotech a strong foothold in the Specialty Clinical Chemistry marketplace while expanding our broad portfolio of diagnostic tests," Mr Ronan O'Caoimh, Trinity Biotech CEO said.
"The addition of these new products will increase the efficiency and effectiveness of our direct sales forces in the USA, Germany and UK and enhance our distribution channels", he added.